SBIR/STTR Research Award
Algae-expressed colostrum protein as prophylaxis for enterotoxigenic E. coli
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TRITON ALGAE INNOVATIONS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- FQ5GJ4C992J3
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Enterotoxigenic E. coli (ETEC) is the leading cause of diarrheal disease among children less than three years of age in developing countries and in travelers to these areas, with over 200 million cases annually, and 380,000 associated deaths. ETEC is transmitted by food or water contaminated with feces, and illness is characterized by profuse watery diarrhea lasting for several days to weeks. Prophylactic prevention of ETEC disease is currently unavailable, and antibiotic-resistant strains of ETEC have emerged. Triton Animal Products, Inc. is developing a therapeutic protein, mammary-associated serum amyloid A3 (MAA) that may offer prophylactic protection against ETEC infections. MAA is an orally-active, evolutionarily conserved protein present in colostrum - an early form of breast milk. MAA is an innate immune factor that stimulates intestinal epithelial cells to secrete mucin, which provides a natural protective barrier that inhibits adherence and colonization of e
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II: Production of an affordable synthetic colostrum replacer in edible green algae
- SBIR Phase I: Production of an affordable synthetic colostrum replacer in edible green algae
- Development of an Improved Bio-Manufacturing Platform for the Production of Glyco
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
4 SBIR/STTR records share this UEI (2014–2016). Reported award amounts total $1,135,680. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation